2018 Innovations in Drug Delivery, Cancer Immunotherapies, Biomarker Identification, and Gene Therapy for Preventing Vision Loss - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Innovations in Drug Delivery, Cancer Immunotherapies, Biomarker Identification, and Gene Therapy for Preventing Vision Loss” report has been added to ResearchAndMarkets.com’s offering.
This Genetic Technology TOE depicts life sciences trends across drug delivery platforms, cancer immunotherapies, biomarker identification, and gene therapy.
Among the therapeutic areas in focus, age-related macular degeneration (AMD), aggressive childhood cancers, and bladder cancer, are of note.
Clinical trial analysis of recombinant drugs for different forms of cancer is also presented.
Key Topics CoveredAdvancements in Mode of Drug Delivery for Age-related Macular Degeneration Immunotherapy Developments for Aggressive Childhood Cancers Novel Biomarkers for p53-like Subtype of Bladder Cancer Novel Gene Therapy Construct that Halts Vision Loss Clinical Trial Analysis of Recombinant Drugs for Different Forms of Cancer Key Contacts
For more information about this report visit https://www.researchandmarkets.com/research/3bvvvg/2018_innovations?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005794/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Genomics,Drug Delivery,Oncology Drugs,Biomarkers
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS ONCOLOGY OPTICAL PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/19/2018 03:57 PM/DISC: 09/19/2018 03:57 PM